Jan 29, 2024 · Gilead and Arcus have reprioritized the joint domvanalimab development program to focus on advancing and potentially accelerating the Phase 3 studies STAR-121 (lung cancer) and STAR-221 (gastrointestinal cancer), which are both expected to be fully enrolled by year-end.

Explore career opportunities and jobs at Gilead Sciences, a biopharma company with an inclusive culture where all employees can help build a healthier world.

Learn about the biopharmaceutical company Gilead Sciences, including mission, vision, values, history, impact, leadership, therapeutic areas and other information.

Gilead Sciences, a biopharma company, achieves bold ambitions to help make the world a healthier place, leading in HIV, liver disease, cancer & inflammation.

Gilead offers a Total Rewards portfolio designed to optimize our employees’ performance, support their wellbeing and allow them to focus on mission-critical work. Our offerings include competitive compensation, stock grants and medical, dental

Sep 10, 2024 · -- Gilead and Genesis Will Leverage the GEMS AI Platform to Generate and Jointly Optimize Molecules Against Selected Targets -- -- Gilead Receives Exclusive Rights to Develop and Commercialize Products from the Collaboration --

This is our global website, intended for visitors seeking information on Gilead’s worldwide business. Some content on this site is not intended for people outside the United States. Visit …

Gilead provides a practical paid internship experience. For 10 to 12 weeks during the summer, you’ll gain real-life work experiences and make valuable connections at the Foster City, Calif. campus.

Dec 3, 2024 · – Single-Asset Focused Collaboration, License, and Option Agreement Combines Tubulis’ Differentiated ADC Platform Technologies with Gilead’s Oncology Research and Development Expertise – – Agreement Provides Gilead with Exclusive Option to License the Resulting ADC Program for Further Development –

Nov 13, 2024 · Gilead continues to focus on global access strategies, including for low-, middle- and high-income countries. Data from both PURPOSE 1 and PURPOSE 2 will support a series of global regulatory filings for lenacapavir for PrEP that will begin by the end of 2024.